Disposition kinetics of furosemide in dogs. 1981

M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef

In 12 experiments on 6 mongrel dogs, furosemide was given both orally and i.v. in a dose of 20mg/kg. Following i.v. injection, the blood concentration curve followed an open one-compartment model. The elimination half-lives after both oral and i.v. routes were nearly similar, i.e. 1.42 +10.13 and 1.13 +0.06 hours respectively. The apparent volume of distribution corresponded well to the total body water (about 60%), i.e. 69.64 +5.61 and 52.06+4.82% b.wt. after oral and i.v. routes respectively. The body clearance of this drug after i.v. and oral administration showed close values, i.e. 5.27 +0.19 and 5.96 +0.14 mg/kg(-1) min(-1) respectively. The systemic bioavailablity of furosemide after oral administration amounted to 77.13 +5.24% with a maximum blood conc. (Cmax.) of 22.73 +2.03 microgram/ml, 30 min after administration.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
March 1981, The Journal of pharmacology and experimental therapeutics,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
December 1969, Journal of pharmaceutical sciences,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
June 1984, Journal of pharmaceutical sciences,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
September 1980, Toxicology and applied pharmacology,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
June 1982, Clinical pharmacology and therapeutics,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
May 1978, The Journal of pharmacology and experimental therapeutics,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
October 1978, Journal of pharmacokinetics and biopharmaceutics,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
March 1993, Biopharmaceutics & drug disposition,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
July 1970, The Journal of pharmacology and experimental therapeutics,
M G El-Sayed, and M Atef, and A Y El-Gendi, and S A Youssef
February 1987, Journal of pharmacokinetics and biopharmaceutics,
Copied contents to your clipboard!